Latanoprost more cost-effective than the rest

Article

Latanoprost offers a more cost-effective strategy for the treatment of glaucoma than either dorzolamide or brimonidine.

Latanoprost offers a more cost-effective strategy for the treatment of glaucoma than either dorzolamide or brimonidine, according to a study published in the February issue of the Canadian Journal of Ophthalmology.

Jean Lachaine and colleagues from the University of Ottawa Eye Institute, Ottawa, Canada conducted an economic analysis of the cost-effectiveness of prostaglandin analogues. Latanoprost was compared with timolol, dorzolamide and brimonidine, while travoprost was compared with timolol separately.

Compared with latanoprost, dorzolamide was not a cost-effective strategy. Compared with brimonidine, latanoprost provided a higher intraocular pressure (IOP) reduction with an incremental cost-effectiveness ratio of $16.17. However, the additional IOP reduction with latanoprost was obtained at a cost higher than the average cost per mmHg reduction obtained with brimonidine. Compared with timolol, latanoprost had a positive incremental cost-effectiveness ratio of $34.48 and $39.06, respectively.

As a first-line treatment for glaucoma, latanoprost is a more cost-effective strategy than dorzolamide and brimonidine. Latanoprost and travoprost are more effective than timolol but also more expensive. For those for whom timolol is not contraindicated, it may be preferable, from a cost-effectiveness point of view, to initiate treatment with timolol and reserve the prostaglandin analogues as an alternative treatment or as an add-on therapy for patients who do not achieve the required results with timolol alone.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.